Galectin Therapeutics (GALT) Accounts Payables (2010 - 2026)

Galectin Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 52.23% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 52.23% decrease from a year earlier, with the FY2025 full-year figure at $3.2 million, down 42.63% from the prior year.
• Accounts Payables fell to $3.1 million in Q1 2026 per GALT's latest filing, from $3.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $6.5 million in Q1 2025 and bottomed at $1.9 million in Q1 2022.
• The 5-year median for Accounts Payables is $3.2 million (2025), against an average of $3.8 million.
• Across the five-year window, Accounts Payables soared 398.95% in 2022 and tumbled 52.23% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $3.9 million in 2022, then surged by 65.32% to $6.4 million in 2023, then retreated by 12.05% to $5.7 million in 2024, then tumbled by 42.63% to $3.2 million in 2025, then declined by 3.82% to $3.1 million in 2026.
• Per Business Quant, the three latest GALT Accounts Payables figures stand at $3.1 million (Q1 2026), $3.2 million (Q4 2025), and $5.4 million (Q3 2025).